Agents for inhibiting proliferation of obinutuzumab-resistant CD20-positive cancer cells, and pharmaceutical compositions, medicines, manufacture, methods for inhibiting proliferation of cells, methods of treatment, type II anti-CD20 antibodies, compounds, and combinations thereof, enhancers, and inducers related thereto

Combining type II anti-CD20 antibodies with chemotherapy agents like prednisolone and doxorubicin enhances treatment efficacy against obinutuzumab-resistant CD20-positive cancers, particularly B-cell non-Hodgkin's lymphoma, by inducing cell cycle arrest and cell death.

JP7590334B2Active Publication Date: 2024-11-26CHUGAI PHARMA CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021550624
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-10-04
Filing Date
2020-09-18
Publication Date
2024-11-26
Estimated Expiration
2040-09-18

Smart Images

  • Figure 0007590334000004
    Figure 0007590334000004
  • Figure 0007590334000005
    Figure 0007590334000005
  • Figure 0007590334000006
    Figure 0007590334000006
Patent Text Reader

Abstract

Among CD20-positive cancers, some develop a resistance to obinutuzumab and some reappear after being treated with the use of obinutuzumab. According to the present invention, against a CD20-positive cancer resistant to obinutuzumab or a CD20-positive cancer reappearing after being treated with the use of obinutuzumab, a type II anti-CD20 antibody is used together with at least one compound selected from the group consisting of prednisolone, doxorubicin, vincristine, salts thereof and prodrugs thereof. Among these compounds, prednisolone, doxorubicin, salts thereof and prodrugs thereof may be selected. Among these compounds, moreover, prednisolone, salts thereof and prodrugs thereof may be selected.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Use of type II anti-CD20 antibodies with increased antibody-dependent cytotoxic activity (ADCC) in combination with cyclophosphamide, vincristine, and doxorubicin for the treatment of non-Hodgkin lymphoma.

    JP2011515428A

  • A pharmaceutical composition

    WO2019017499A2